Early tocilizumab and outcomes in acute necrotizing encephalopathy

Treating a rare, severe infection-related childhood brain illness earlier may improve recovery. When children catch common infections like the flu or COVID-19, a rare but very serious complication can sometimes follow. The body's defence system may overreact and accidentally injure the brain. This is called acute necrotizing encephalopathy (ANE). It can develop within hours, and many children die or are left with permanent impairments. Standard treatments including steroids are given to calm the immune system, but these are often insufficient. Doctors have begun using a medicine called tocilizumab, which switches off one of the immune system's main alarm signals that drives the damage. Until now, it was not clear how well it works, when it should be given, or whether it is safe in children with very severe issues. Doctors from hospitals in five countries reviewed the cases of 63 children with ANE who were given tocilizumab, alongside the usual treatments, between 2018 and 2023. They wanted to find out whether the timing of the medicine made a difference. The results were insightful. Children who received tocilizumab early — within 3 days of falling ill — recovered far better than those who were treated later. A year after their illness, children treated early were much more likely to be living independently, even among those who had been the most severely affected. Just as importantly, the medicine caused no harmful side effects.